Citi cuts Illumina target, places on ‘negative catalyst watch’
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy ILMN?
Source: Business Insider
Citi's Price Target Adjustment: Citi has reduced Illumina's price target from $130 to $90 while maintaining a Neutral rating, citing multiple challenges the company is facing, including being placed on China's "unreliable entities" list.
Impact of China on Revenue: The firm highlights that China accounts for 7% of Illumina's total revenue and remains a crucial market despite recent developments affecting the company's operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 141.880
Low
40.50
Averages
133.54
High
170.00
Current: 141.880
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Markets Hit New Highs as Tech Stocks Surge
- Tech Stocks Surge: Stocks like Lumentum, Coherent, Corning, Western Digital, Micron, Seagate, Qualcomm, and Qnity Electronics have all risen over 5%, indicating strong market confidence in the tech sector, which may drive overall market gains further.
- Energy Stocks Rise: Energy stocks increased alongside oil prices after President Trump indicated challenges to the Iran ceasefire, reflecting market sensitivity to energy price fluctuations that could impact consumer spending and overall economic growth.
- Consumer Confidence Dips: Consumer-related stocks, including TJX Companies and Nike, faced declines, highlighting investor anxiety over the potential economic pressures from rising energy prices, which could dampen consumer spending.
- CPI Report Expectations: The upcoming Consumer Price Index report is expected to show a significant month-over-month increase, with economists predicting a 0.59% rise from March, which may prompt government actions to alleviate economic burdens on consumers, further influencing market sentiment.
See More
Trump Invites Top Executives for China Trip
- Executive Delegation: President-elect Trump has invited top executives, including Tesla's Elon Musk and Apple's Tim Cook, to join his trip to China, aiming to enhance U.S.-China business cooperation through high-level engagement.
- Broad Agenda: The summit is expected to cover a wide range of topics, including trade, artificial intelligence, export controls, Taiwan, and the Iran war, indicating a desire to ease tensions through dialogue after recent escalations.
- Business Deal Expectations: Trump hopes to secure a series of business deals and purchase agreements during the visit, which, if successful, could enhance U.S. companies' competitiveness in the Chinese market and foster bilateral economic relations.
- Diverse Executive List: The delegation includes executives from various sectors, such as Stephen Schwarzman of Blackstone and Jane Fraser of Citigroup, reflecting U.S. companies' commitment to the Chinese market and willingness to collaborate.
See More
Illumina Reports Q1 Results Exceeding Revenue Expectations
- Performance Exceeds Expectations: Illumina's Q1 revenue reached $1.09 billion, reflecting a 4.8% year-on-year growth that surpassed analyst expectations of $1.07 billion, indicating strong performance in the genomics sector and potential for stock price appreciation.
- Profitability Improvement: The adjusted EPS was $1.15, exceeding the $1.05 consensus estimate by 9%, while adjusted operating income stood at $239 million with a 21.9% margin, showcasing the company's success in cost control and operational efficiency.
- Strong Clinical Demand: Clinical sequencing now accounts for over 65% of the company's consumables revenue, with more than 80 NovaSeq X instruments placed in the quarter, driving revenue growth and indicating sustained demand for high-throughput sequencing.
- Innovation-Driven Growth: Illumina plans to launch new high-throughput flow cells and spatial transcriptomics solutions to enhance the capabilities of the NovaSeq X platform, expected to further expand market share and strengthen competitive positioning.
See More
Illumina Q1 2026 Earnings Call Highlights
- Performance Exceeds Expectations: Illumina reported Q1 revenue of $1.09 billion, exceeding the midpoint of guidance by $20 million, primarily driven by strong instrument and clinical consumable sales, indicating sustained growth potential in clinical markets.
- Guidance Raised for the Year: Management raised the 2026 revenue outlook to $4.52 billion to $4.62 billion and non-GAAP EPS expectations to $5.15 to $5.30, reflecting confidence in future performance and robust market demand.
- Product Innovation Progress: Illumina launched TruPath and is on track to introduce its spatial transcriptomics offering later this year, showcasing the company's ongoing commitment to technological innovation aimed at solidifying its market leadership.
- Expanded Buyback Program: The company repurchased 2 million shares for approximately $242 million in Q1 and announced an additional $1.5 billion share repurchase program, demonstrating management's confidence in future growth and commitment to shareholders.
See More
Apple Beats Earnings Expectations, Roku Shares Surge 6%
- Apple's Strong Earnings: Apple reported fiscal Q2 earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating robust competitiveness in the overall market.
- Roku's Impressive Performance: Roku's Q1 revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the $131.3 million forecast, and the company anticipates continued outperformance in upcoming quarters, highlighting its growth potential in the streaming market.
- Twilio's Strong Rebound: Twilio reported Q1 adjusted earnings of $1.50 per share, beating the $1.27 estimate, with revenue of $1.41 billion also exceeding the $1.34 billion expectation, showcasing sustained growth and strong market demand in the cloud communications sector.
- GoDaddy's Excellent Results: GoDaddy's Q1 earnings were $1.60 per share on revenue of $1.27 billion, both surpassing analyst expectations of $1.52 and $1.26 billion, while free cash flow of $473.6 million exceeded the anticipated $454.2 million, indicating strong competitiveness and profitability in the website building market.
See More
Illumina Set to Announce Q1 Earnings with Positive Estimates
- Earnings Announcement Date: Illumina (ILMN) is set to release its Q1 2023 earnings on April 30th after market close, with consensus EPS estimates at $1.05, reflecting an 8.2% year-over-year increase, and revenue estimates at $1.07 billion, indicating a 2.9% year-over-year growth, showcasing the company's stable growth potential in the market.
- Historical Performance Review: Over the past two years, Illumina has exceeded EPS and revenue estimates 88% of the time, demonstrating reliability in profitability and market performance, which enhances investor confidence in the stock.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and ten downward revisions, while revenue estimates experienced seven upward revisions and one downward revision, reflecting a cautious market sentiment regarding the company's future performance.
- Long-Term Growth Outlook: Illumina's revenue guidance for 2026 is set between $4.5 billion and $4.6 billion, indicating ongoing advancements in clinical growth and multiomics strategy, which suggests significant future growth potential and competitive strength in the market.
See More
Markets Hit New Highs as Tech Stocks Surge
- Tech Stocks Surge: Stocks like Lumentum, Coherent, Corning, Western Digital, Micron, Seagate, Qualcomm, and Qnity Electronics have all risen over 5%, indicating strong market confidence in the tech sector, which may drive overall market gains further.
- Energy Stocks Rise: Energy stocks increased alongside oil prices after President Trump indicated challenges to the Iran ceasefire, reflecting market sensitivity to energy price fluctuations that could impact consumer spending and overall economic growth.
- Consumer Confidence Dips: Consumer-related stocks, including TJX Companies and Nike, faced declines, highlighting investor anxiety over the potential economic pressures from rising energy prices, which could dampen consumer spending.
- CPI Report Expectations: The upcoming Consumer Price Index report is expected to show a significant month-over-month increase, with economists predicting a 0.59% rise from March, which may prompt government actions to alleviate economic burdens on consumers, further influencing market sentiment.
See More
Trump Invites Top Executives for China Trip
- Executive Delegation: President-elect Trump has invited top executives, including Tesla's Elon Musk and Apple's Tim Cook, to join his trip to China, aiming to enhance U.S.-China business cooperation through high-level engagement.
- Broad Agenda: The summit is expected to cover a wide range of topics, including trade, artificial intelligence, export controls, Taiwan, and the Iran war, indicating a desire to ease tensions through dialogue after recent escalations.
- Business Deal Expectations: Trump hopes to secure a series of business deals and purchase agreements during the visit, which, if successful, could enhance U.S. companies' competitiveness in the Chinese market and foster bilateral economic relations.
- Diverse Executive List: The delegation includes executives from various sectors, such as Stephen Schwarzman of Blackstone and Jane Fraser of Citigroup, reflecting U.S. companies' commitment to the Chinese market and willingness to collaborate.
See More
Illumina Reports Q1 Results Exceeding Revenue Expectations
- Performance Exceeds Expectations: Illumina's Q1 revenue reached $1.09 billion, reflecting a 4.8% year-on-year growth that surpassed analyst expectations of $1.07 billion, indicating strong performance in the genomics sector and potential for stock price appreciation.
- Profitability Improvement: The adjusted EPS was $1.15, exceeding the $1.05 consensus estimate by 9%, while adjusted operating income stood at $239 million with a 21.9% margin, showcasing the company's success in cost control and operational efficiency.
- Strong Clinical Demand: Clinical sequencing now accounts for over 65% of the company's consumables revenue, with more than 80 NovaSeq X instruments placed in the quarter, driving revenue growth and indicating sustained demand for high-throughput sequencing.
- Innovation-Driven Growth: Illumina plans to launch new high-throughput flow cells and spatial transcriptomics solutions to enhance the capabilities of the NovaSeq X platform, expected to further expand market share and strengthen competitive positioning.
See More
Illumina Q1 2026 Earnings Call Highlights
- Performance Exceeds Expectations: Illumina reported Q1 revenue of $1.09 billion, exceeding the midpoint of guidance by $20 million, primarily driven by strong instrument and clinical consumable sales, indicating sustained growth potential in clinical markets.
- Guidance Raised for the Year: Management raised the 2026 revenue outlook to $4.52 billion to $4.62 billion and non-GAAP EPS expectations to $5.15 to $5.30, reflecting confidence in future performance and robust market demand.
- Product Innovation Progress: Illumina launched TruPath and is on track to introduce its spatial transcriptomics offering later this year, showcasing the company's ongoing commitment to technological innovation aimed at solidifying its market leadership.
- Expanded Buyback Program: The company repurchased 2 million shares for approximately $242 million in Q1 and announced an additional $1.5 billion share repurchase program, demonstrating management's confidence in future growth and commitment to shareholders.
See More
Apple Beats Earnings Expectations, Roku Shares Surge 6%
- Apple's Strong Earnings: Apple reported fiscal Q2 earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating robust competitiveness in the overall market.
- Roku's Impressive Performance: Roku's Q1 revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the $131.3 million forecast, and the company anticipates continued outperformance in upcoming quarters, highlighting its growth potential in the streaming market.
- Twilio's Strong Rebound: Twilio reported Q1 adjusted earnings of $1.50 per share, beating the $1.27 estimate, with revenue of $1.41 billion also exceeding the $1.34 billion expectation, showcasing sustained growth and strong market demand in the cloud communications sector.
- GoDaddy's Excellent Results: GoDaddy's Q1 earnings were $1.60 per share on revenue of $1.27 billion, both surpassing analyst expectations of $1.52 and $1.26 billion, while free cash flow of $473.6 million exceeded the anticipated $454.2 million, indicating strong competitiveness and profitability in the website building market.
See More
Illumina Set to Announce Q1 Earnings with Positive Estimates
- Earnings Announcement Date: Illumina (ILMN) is set to release its Q1 2023 earnings on April 30th after market close, with consensus EPS estimates at $1.05, reflecting an 8.2% year-over-year increase, and revenue estimates at $1.07 billion, indicating a 2.9% year-over-year growth, showcasing the company's stable growth potential in the market.
- Historical Performance Review: Over the past two years, Illumina has exceeded EPS and revenue estimates 88% of the time, demonstrating reliability in profitability and market performance, which enhances investor confidence in the stock.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and ten downward revisions, while revenue estimates experienced seven upward revisions and one downward revision, reflecting a cautious market sentiment regarding the company's future performance.
- Long-Term Growth Outlook: Illumina's revenue guidance for 2026 is set between $4.5 billion and $4.6 billion, indicating ongoing advancements in clinical growth and multiomics strategy, which suggests significant future growth potential and competitive strength in the market.
See More
